Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | GLS | O94925 | 5/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847465 | 1.00 | CHRM3 (0.43) | CHRM3NOTUMEPHX2EPHX1GLS | |
| SCHEMBL4117389 | 0.95 | CHRM3 (0.42) | CHRM3NOTUMEPHX2EPHX1GLS | |
| SCHEMBL4847784 | 0.95 | CHRM3 (0.42) | CHRM3NOTUMEPHX2EPHX1GLS | |
| SCHEMBL4101320 | 0.85 | CHRM3 (0.45) | CHRM3EPHX2EPHX1C3AR1 | |
| SCHEMBL3955877 | 0.84 | SLC6A2 (0.46) | NOTUMEPHX2GLSHSD11B1 | |
| SCHEMBL3961750 | 0.84 | SLC6A2 (0.46) | NOTUMEPHX2GLSHSD11B1 | |
| SCHEMBL4758293 | 0.82 | CHRM3 (0.47) | CHRM3C3AR1 | |
| SCHEMBL4114787 | 0.82 | EPHX2 (0.54) | CHRM3EPHX2EPHX1 | |
| SCHEMBL3952527 | 0.80 | SLC6A2 (0.45) | NOTUM | |
| SCHEMBL3955180 | 0.80 | SLC6A2 (0.45) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | CHRM3 853/4885NOTUM 2347/4885EPHX2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.